MEDISCA $100,000 Pledge to Protect Compounded Hormone Therapy Encourages Industry-wide Response - Doubling Donations in 1 Month.

PLATTSBURGH, N.Y.--(BUSINESS WIRE)--Earlier this year MEDISCA announced that in June it would match up to $100,000 in donations to the Alliance for Pharmacy Compounding (APC) Media Fund Campaign, encouraging investments to support APC’s nationwide marketing and lobbying effort to secure compounded hormone therapy. The result was astonishing, bringing in $113,545 in investments from compounding pharmacies, which, with Medisca’s match, elevated the final amount raised in June to $213,545.

“Our objective with the pledge was simple – to create a wave of support from our industry – and we were blown away by the result, ” said Andrew Rowe, Medisca’s Senior Vice President. “APC has stepped up to the plate as our voice in the fight to maintain compounded hormone therapy amidst the current threats. Whether you are a fellow compounding supplier, compounding advocate, compounding pharmacist, or compounding provider, now is the time to unify together and support APC’s efforts to secure our industry.”

Compounded hormone medications are estimated to serve over 8 million patients in the United States and represent a significant portion of compounding pharmacy revenue. Imposing restrictions to these medications, would have significant downstream effects on local compounding pharmacy businesses and patient access to critically important medical therapy.

“We are amazed at the effect Medisca’s challenge had on our fundraising campaign,” said APC’s CEO Scott Brunner, CAE. “It was a whopping success, especially in the final days of the Medisca Challenge, and has put us awfully close to our goal – only about $300,000 to go. We are so grateful to our partner Medisca for their leadership and support in this important effort. Now let’s finish the job!”

To donate to the cause, click here and to learn more about APC’s efforts to secure compounded hormone therapy, visit www.compounding.com.

About MEDISCA

MEDISCA is the leader in providing turnkey solutions to the pharmaceutical compounding industry and allied health care professionals worldwide. Committed to being a complete resource for prescribers, pharmacists and pharmacy technicians engaged in personalized medicine, MEDISCA offers high quality products, industry-leading support, and first-class education through its partner LP3 Network. Founded in 1989, the company has locations in Canada, the United States and Australia, optimizing its service to the international market. For more information about MEDISCA, please visit www.medisca.com and follow us on Twitter at @medisca.

To access more information, campaign resources, or donation opportunities regarding compounded hormone therapy, please visit www.a4pc.org or www.compounding.com